3-V appoints George Kemble CSO
This article was originally published in Scrip
3-V Biosciences, a privately-held biopharmaceutical company developing novel antiviral therapeutics, has appointed Dr George Kemble chief scientific officer. Dr Kemble most recently served as senior vice-president of R&D for MedImmune, a subsidiary of AstraZeneca, responsible for the development of multiple products, including FluMist (influenza vaccine live, intranasal).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.